

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

Capitol Annex -Room 131

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, March 21, 2019

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Epidiolex™ (Anticonvulsants)
 - ii. Ajovy™ (Antimigraine, Other)
 - iii. Emgality™ (Antimigraine, Other)
 - iv. Talzenna™ (Oncology, Oral – Breast Cancer)
 - v. Copiktra™ (Oncology, Oral – Hematologic Cancer)
 - vi. Daurismo™ (Oncology, Oral – Hematologic Cancer)
 - vii. Xospata® (Oncology, Oral – Hematologic Cancer)
 - viii. Lorbrena® (Oncology, Oral – Lung Cancer)
 - ix. Vizimpro® (Oncology, Oral – Lung Cancer)
 - b. New Products to Market to be reviewed along with their respective classes:
 - i. Arikayce® (Antibiotics, Inhaled)
 - ii. Xofluza™ (Antivirals, Oral)
 - iii. Yupelri™ (COPD Agents)
- V. Clinical Criteria Review**
 - a. Ocaliva Criteria Review
 - b. Hepatitis C Prescriber Restrictions
- VI. Therapeutic Classes with Recommended Changes**
 - a. Antibiotics, Inhaled (includes new agent Arikayce®)
 - b. Antivirals, Oral
 - i. Antivirals: Herpes
 - ii. Antivirals: Influenza (includes new agent Xofluza™)
 - c. Cephalosporins and Related Antibiotics
 - i. Antibiotics: Cephalosporins 1st Generation
 - ii. Antibiotics: Cephalosporins 2nd Generation
 - iii. Antibiotics: Cephalosporins 3rd Generation
 - d. COPD Agents (includes new agent Yupelri™)
 - e. Hepatitis B Agents
 - f. HIV/AIDS

VII. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Absorbable Sulfonamides	Hypoglycemics, Insulin and Related Agents
Antibiotics, GI	Hypoglycemics, Meglitinides
Antibiotics, Vaginal	Hypoglycemics, Metformins
Antifungals, Oral	Hypoglycemics, SGLT2
Antihistamines, Minimally Sedating	Hypoglycemics, Sulfonylureas
Bronchodilators, Beta Agonist	Hypoglycemics, Thiazolidinediones (TZD)
Epinephrine, Self-Injected	Intranasal Rhinitis Agents
Fluoroquinolones, Oral	Leukotriene Modifiers
Glucocorticoids, Inhaled	Macrolides
Hepatitis C Agents	Oxazolidinediones
Hypoglycemics, Alpha-Glucosidase Inhibitors	Penicillins
Hypoglycemics, Incretin Mimetics/Enhancers	Tetracyclines

VIII. Adjournment

- a. Schedule of Upcoming Meetings
- i. **May 16, 2019**
 - ii. **July 18, 2019**
 - iii. **September 19, 2019**
 - iv. **November 21, 2019**
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.